BC Innovations | Jul 18, 2019
Distillery Therapeutics

Inhibiting EZH2 for myeloma-associated bone loss

DISEASE CATEGORY: Musculoskeletal INDICATION: Bone repair Inhibiting EZH2 could help repair myeloma-associated bone loss. Among 20 myeloma patients in remission, levels of EZH2 mRNA in bone marrow adipocytes, which are associated with bone loss, correlated...
BC Innovations | Jun 27, 2019
Distillery Therapeutics

Inhibiting EZH2 for colitis and colitis-associated colorectal cancer

DISEASE CATEGORY: Gastrointestinal; cancer INDICATION: Colitis; colorectal cancer Inhibiting EZH2 could help treat colitis and colitis-associated colorectal cancer. The EZH2 inhibitor GSK2816126 or a tool compound EZH2 inhibitor increased survival and colon length, which is...
BC Innovations | Feb 20, 2019
Distillery Therapeutics

Autoimmune disease

INDICATION: Scleroderma Patient sample and mouse studies suggest inhibiting EZH2 could help treat scleroderma. In fibroblasts from patients with diffuse cutaneous scleroderma, levels of EZH2 mRNA were higher than in fibroblasts from healthy volunteers. In...
BC Week In Review | Jul 20, 2018
Financial News

Constellation raises $60M in NASDAQ IPO

Epigenetics company Constellation Pharmaceuticals Inc. (NASDAQ:CNST) raised $60 million on July 18 through the sale of 4 million shares at $15 in a downsized IPO. Underwriters are J.P. Morgan, Jefferies, BMO Capital Markets and Oppenheimer....
BC Innovations | Jul 19, 2018
Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
BC Extra | Jul 19, 2018
Financial News

Constellation slips after pricing $60M IPO

Constellation Pharmaceuticals Inc. (NASDAQ:CNST) dipped $3.52 (23%) to $11.48 Thursday after it raised $60 million through the sale of 4 million shares at $15 in a downsized IPO. Underwriters are J.P. Morgan, Jefferies, BMO Capital...
BC Innovations | Jul 17, 2018
Distillery Therapeutics


INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting EZH2 or promoting FOXC1 expression could help treat the luminal B subtype of metastatic breast cancer. In patients with luminal B-type breast cancer,...
BC Extra | Jun 23, 2018
Financial News

Latest batch of IPO filings: Rubius, Constellation, Replimune, Allakos

As a busy week for IPO pricings came to a close, several more companies filed for NASDAQ listings late Friday, further stocking an IPO pipeline of companies likely to seek liquidity during a tight calendar...
BC Extra | Apr 23, 2018
Clinical News

FDA places hold on Epizyme's tazemetostat

Epizyme Inc. (NASDAQ:EPZM) fell $2.90 (19%) to $12.40 in after-hours trading Monday after FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438) following a report of a patient who developed secondary T cell lymphoma...
BC Week In Review | Apr 13, 2018
Financial News

Constellation raises $100M

Cancer epigenetics company Constellation Pharmaceuticals Inc. (Cambridge, Mass.) raised $100 million on April 9 in an untranched venture round from new investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed and...
Items per page:
1 - 10 of 25